欧州医薬品庁(EMA)が、レンバチニブについて、進行または切除不能な肝細胞がんの一次治療における適応拡大を支持

EMA Recommends Extension of Indications for Lenvatinib

On 28 June 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product lenvatinib (Lenvima).

 

 

 

コメント

Leave a comment

Your email address will not be published.


*